ANI Pharmaceuticals

Yahoo Finance • 9 days ago

ANI Pharmaceuticals Refocuses On Rare Disease As Buybacks And Insider Sales Rise

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. ANI Pharmaceuticals (NasdaqGM:ANIP) is sharpening its focus on specialty and rare disease products, including Cortrophin Gel and I... Full story

Yahoo Finance • 28 days ago

Unpacking Q4 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) In The Context Of Other Pharmaceuticals Stocks

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Jazz Pharmaceuticals (NASDAQ:JAZZ) and the best and worst performers in the pharma... Full story

Yahoo Finance • last month

ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET

PRINCETON, N.J., April 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its first quarter 2026 financial results on Friday, May 8, 2026, prior to the... Full story

Yahoo Finance • last month

ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity

PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI’s Pimozide Tablets is the generic version of the referenc... Full story

Yahoo Finance • last month

1 Small-Cap Stock for Long-Term Investors and 2 We Turn Down

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it ha... Full story

Yahoo Finance • last month

ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules

PRINCETON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Carbamazepine Extended-Release Capsules, 100 mg, 200 mg and 300 mg. ANI’s Carbamazepine Exten... Full story

Yahoo Finance • 2 months ago

Artivion, ANI Pharmaceuticals, and Privia Health Shares Are Soaring, What You Need To Know

What Happened? A number of stocks jumped in the afternoon session after the government announced a surprise increase in payment rates for Medicare Advantage plans. This change raises the revenue that insurance companies receive per patie... Full story

Yahoo Finance • 2 months ago

Revance CEO Nadeem Moiz on Expansion, Opportunities & Capitalization

By Karen Roman Exec Edge sat down with Nadeem Moiz, Chief Executive Officer at Revance, to learn more about the company’s vision in aesthetics, skincare and therapeutics. Exec Edge: Tell us about Revance and the science-powered products... Full story

Yahoo Finance • 2 months ago

3 Profitable Stocks That Concern Us

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity". Not all profitable comp... Full story

Yahoo Finance • 3 months ago

Clover Health, Alignment Healthcare, Solventum, ANI Pharmaceuticals, and Guardant Health Shares Plummet, What You Need To Know

What Happened? A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. The Producer Price Index (PPI), a key measure of inflation at... Full story

Yahoo Finance • 3 months ago

ANI Pharmaceuticals Reaffirms FY26 Outlook; Swings To Profit In Q4; Stock Up 7.6% - Update

(RTTNews) - Biopharmaceutical company ANI Pharmaceuticals, Inc. (ANIP) reported Friday a net income attributable to common shareholders for the fourth quarter of $27.49 million or $1.18 per share, compared to a net loss of $10.68 million o... Full story

Yahoo Finance • 3 months ago

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET

PRINCETON, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27... Full story

Yahoo Finance • 6 months ago

ANI Pharmaceuticals Announces Formation of “FutureVision Advisory Council” to Help Strategically Guide Ophthalmology and Retina Franchise

PRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that it has established The FutureVision Advisory Council to help guide the strategic advancement of its... Full story

Yahoo Finance • 6 months ago

ANI Pharmaceuticals Announces Board Transition

Patrick D. Walsh steps down as Chairman and will complete his current term as Board member Thomas J. Haughey has been unanimously elected to serve as the next Chairman of the Board PRINCETON, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- A... Full story

Yahoo Finance • 6 months ago

ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare Conference

PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th... Full story

Yahoo Finance • 6 months ago

Relative Strength Alert For ANI Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the R... Full story

Yahoo Finance • 7 months ago

ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance

Record quarterly net revenues of $227.8 million, an increase of 53.6% year-over-yearPurified Cortrophin® Gel net revenues of $101.9 million, an increase of 93.8% year-over-yearRecord quarterly adjusted non-GAAP EBITDA of $59.6 million, an... Full story

Yahoo Finance • 7 months ago

ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET

PRINCETON, N.J., Oct. 24, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its third quarter 2025 financial results on Friday, November 7, 2025, prior to... Full story

Yahoo Finance • 7 months ago

ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting

PRINCETON, N.J., Oct. 16, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that results from the NEW DAY clinical trial of ILUVIEN® (fluocinolone acetonide intravitreal implant),... Full story

Yahoo Finance • 8 months ago

Carlyle Group Reaches Analyst Target Price

In recent trading, shares of Carlyle Group Inc (Symbol: CG) have crossed above the average analyst 12-month target price of $40.27, changing hands for $40.96/share. When a stock reaches the target an analyst has set, the analyst logicall... Full story